Michael Thomas Henderson

Insider Reports History

Location
Palo Alto, CA
Signature
Michael Thomas Henderson
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Michael Thomas Henderson:

Company Role Class Num Shares Value Price $ Report Date Ownership
Apogee Therapeutics, Inc. Chief Executive Officer, Director Common Stock 1,135,987 $95,616,025 $84.17 16 Apr 2026 Direct
Spyre Therapeutics, Inc. Director Common Stock 88,606 $6,676,462 $75.35 08 May 2026 Direct
Apogee Therapeutics, Inc. Chief Executive Officer, Director Stock Option (Right to Buy) 387,012 16 Apr 2026 Direct
Spyre Therapeutics, Inc. Director Stock Option (Right to Buy) 25,000 29 May 2025 Direct
ARYA Sciences Acquisition Corp IV Director Class B ordinary shares 0 31 Jul 2024 Direct

Insider Reports Filed by Michael Thomas Henderson

Symbol Company Period Transactions Value $ Form Type Role Filing Time
SYRE Spyre Therapeutics, Inc. 08 May 2026 4 -$5,952,050 4 Director 08 May 2026, 21:31
APGE Apogee Therapeutics, Inc. 16 Apr 2026 2 $0 4 Chief Executive Officer, Director 20 Apr 2026, 16:05
APGE Apogee Therapeutics, Inc. 08 Apr 2026 3 -$1,651,664 4 Chief Executive Officer, Director 10 Apr 2026, 20:00
APGE Apogee Therapeutics, Inc. 11 Mar 2026 3 -$1,495,605 4 Chief Executive Officer, Director 13 Mar 2026, 20:00
APGE Apogee Therapeutics, Inc. 11 Feb 2026 3 -$1,266,953 4 Chief Executive Officer, Director 13 Feb 2026, 20:00
SYRE Spyre Therapeutics, Inc. 21 Jan 2026 1 $0 4 Director 23 Jan 2026, 21:31
APGE Apogee Therapeutics, Inc. 14 Jan 2026 6 -$1,622,159 4 Chief Executive Officer, Director 16 Jan 2026, 20:00
APGE Apogee Therapeutics, Inc. 02 Jan 2026 1 $0 4 Chief Executive Officer, Director 06 Jan 2026, 20:01
APGE Apogee Therapeutics, Inc. 10 Dec 2025 3 -$1,507,657 4 Chief Executive Officer, Director 12 Dec 2025, 20:00
APGE Apogee Therapeutics, Inc. 04 Dec 2025 1 -$3,000,400 4 Chief Executive Officer, Director 05 Dec 2025, 20:00
APGE Apogee Therapeutics, Inc. 13 Nov 2025 4 -$1,260,236 4 Chief Executive Officer, Director 13 Nov 2025, 20:24
SYRE Spyre Therapeutics, Inc. 29 May 2025 1 $0 4 Director 02 Jun 2025, 16:35
APGE Apogee Therapeutics, Inc. 05 Mar 2025 2 -$301,511 4 Chief Executive Officer, Director 07 Mar 2025, 20:01
APGE Apogee Therapeutics, Inc. 05 Feb 2025 1 -$608,700 4 Chief Executive Officer, Director 07 Feb 2025, 20:01
APGE Apogee Therapeutics, Inc. 31 Jan 2025 2 +$194,310 4 Chief Executive Officer, Director 31 Jan 2025, 20:00
SYRE Spyre Therapeutics, Inc. 10 Jan 2025 1 $0 4 Director 14 Jan 2025, 17:16
APGE Apogee Therapeutics, Inc. 08 Jan 2025 2 -$732,693 4 Chief Executive Officer, Director 10 Jan 2025, 20:00
APGE Apogee Therapeutics, Inc. 09 Dec 2024 1 $0 4 Chief Executive Officer, Director 11 Dec 2024, 20:02
APGE Apogee Therapeutics, Inc. 04 Dec 2024 2 -$698,654 4 Chief Executive Officer, Director 06 Dec 2024, 20:01
APGE Apogee Therapeutics, Inc. 06 Nov 2024 2 -$888,320 4 Chief Executive Officer, Director 08 Nov 2024, 20:01
APGE Apogee Therapeutics, Inc. 02 Oct 2024 2 -$2,249,307 4 Chief Executive Officer, Director 04 Oct 2024, 20:01
APGE Apogee Therapeutics, Inc. 04 Sep 2024 2 -$1,904,841 4 Chief Executive Officer, Director 06 Sep 2024, 20:02
APGE Apogee Therapeutics, Inc. 07 Aug 2024 3 -$1,624,764 4 Chief Executive Officer, Director 09 Aug 2024, 20:05
/report/000114036124035178-henderson-michael-thomas-2024-07-31 ARYA Sciences Acquisition Corp IV 31 Jul 2024 1 $0 4 Director 31 Jul 2024, 21:49
APGE Apogee Therapeutics, Inc. 05 Jul 2024 1 -$558,900 4 Chief Executive Officer, Director 05 Jul 2024, 20:01
SYRE Spyre Therapeutics, Inc. 14 May 2024 1 $0 4 Director 16 May 2024, 16:10
APGE Apogee Therapeutics, Inc. 18 Dec 2023 1 $0 4 Chief Executive Officer, Director 20 Dec 2023, 20:00
APGE Apogee Therapeutics, Inc. 13 Jul 2023 0 $0 3/A Chief Executive Officer, Director 17 Jul 2023, 17:04
SYRE Aeglea BioTherapeutics, Inc. 22 Jun 2023 0 $0 3 Director 30 Jun 2023, 17:13
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .